| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
7,432 |
5,065 |
$2.27M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,077 |
3,618 |
$1.56M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,784 |
2,207 |
$1.08M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
2,851 |
2,137 |
$412K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
834 |
617 |
$291K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,269 |
856 |
$271K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,530 |
1,036 |
$125K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,343 |
1,538 |
$122K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,066 |
1,387 |
$96K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,715 |
2,386 |
$94K |
| 71045 |
Radiologic examination, chest; single view |
2,551 |
1,674 |
$72K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,480 |
1,755 |
$71K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,779 |
499 |
$67K |
| J3490 |
Unclassified drugs |
9,005 |
3,471 |
$58K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
21 |
15 |
$46K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,405 |
994 |
$46K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,416 |
1,018 |
$44K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
578 |
275 |
$38K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,065 |
1,497 |
$33K |
| 71046 |
Radiologic examination, chest; 2 views |
1,097 |
813 |
$33K |
| 80053 |
Comprehensive metabolic panel |
6,180 |
4,262 |
$29K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,735 |
1,435 |
$28K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
46 |
37 |
$27K |
| 80050 |
General health panel |
3,037 |
2,488 |
$24K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,025 |
670 |
$24K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,468 |
1,085 |
$24K |
| 96376 |
|
437 |
292 |
$23K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,520 |
4,300 |
$22K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
73 |
54 |
$20K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
388 |
277 |
$20K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
365 |
296 |
$15K |
| 84484 |
|
3,037 |
1,665 |
$12K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
34 |
33 |
$12K |
| 80061 |
Lipid panel |
1,100 |
963 |
$10K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
425 |
350 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
934 |
398 |
$7K |
| 83690 |
|
1,800 |
1,311 |
$7K |
| 87040 |
|
1,426 |
527 |
$7K |
| 80305 |
|
1,450 |
1,075 |
$7K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
359 |
308 |
$7K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
357 |
306 |
$7K |
| 84443 |
Thyroid stimulating hormone (TSH) |
694 |
559 |
$7K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
332 |
189 |
$7K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,389 |
1,047 |
$6K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
984 |
616 |
$5K |
| 83605 |
|
1,159 |
636 |
$5K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,098 |
648 |
$5K |
| 85610 |
|
2,733 |
1,441 |
$4K |
| 82947 |
|
1,289 |
377 |
$4K |
| 81001 |
|
2,589 |
1,878 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
648 |
550 |
$4K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
602 |
342 |
$4K |
| 87186 |
|
833 |
551 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,457 |
1,081 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,477 |
1,004 |
$3K |
| 83880 |
|
220 |
156 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
152 |
135 |
$3K |
| 84703 |
|
573 |
472 |
$3K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
56 |
40 |
$3K |
| 83735 |
|
705 |
516 |
$3K |
| 73610 |
|
39 |
27 |
$2K |
| 87088 |
|
871 |
657 |
$2K |
| 81025 |
|
432 |
346 |
$2K |
| J2704 |
Injection, propofol, 10 mg |
75 |
43 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
9,532 |
6,665 |
$2K |
| 85027 |
|
406 |
315 |
$2K |
| 85379 |
|
284 |
237 |
$2K |
| 81003 |
|
1,371 |
1,003 |
$1K |
| 87077 |
|
249 |
174 |
$1K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
82 |
68 |
$1K |
| 99001 |
|
165 |
150 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
92 |
70 |
$1K |
| 97162 |
|
18 |
14 |
$889.55 |
| 86317 |
|
82 |
64 |
$876.60 |
| 87081 |
|
172 |
134 |
$736.08 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
78 |
55 |
$678.65 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
77 |
41 |
$558.59 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
18 |
14 |
$512.42 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
227 |
157 |
$493.75 |
| 80074 |
|
15 |
13 |
$473.57 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
138 |
117 |
$401.52 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
81 |
42 |
$391.76 |
| 87449 |
|
45 |
39 |
$352.52 |
| J2060 |
Injection, lorazepam, 2 mg |
93 |
57 |
$206.88 |
| 80076 |
|
32 |
27 |
$197.47 |
| 86140 |
|
33 |
26 |
$196.45 |
| 85730 |
|
64 |
55 |
$194.39 |
| 84439 |
|
26 |
12 |
$132.87 |
| 82728 |
|
12 |
12 |
$123.22 |
| 36416 |
|
156 |
104 |
$55.37 |
| 85652 |
|
31 |
25 |
$46.81 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
17 |
12 |
$42.66 |
| 87205 |
|
16 |
15 |
$40.93 |